License Agreement to Expand its CRISPR/Cas9 Gene Editing Services

Taconic Biosciences, a global leader in providing animal model solutions and services, entered into an exclusive license agreement with Helmholtz Munich to provide preclinical researchers with advanced CRISPR gene editing services. Through this agreement, Taconic Biosciences has acquired the exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich to improve the generation of genetically modified mouse models  for biomedical research.

"Taconic is excited to expand our already extensive capabilities in CRISPR/Cas9 gene editing through this new partnership with Helmholtz Munich,” said Mike Garrett, Chief Executive Officer of Taconic Biosciences. “This technology significantly enhances Taconic’s ExpressMODEL® platform to deliver high-quality, precise CRISPR/Cas9-generated custom models on an accelerated timeline to our customers."

"This agreement with Taconic Biosciences will deepen our understanding of gene function by enabling the development of advanced, genetically engineered mouse models ," said Prof. Dr. Wolfgang Wurst, co-inventor of the licensed technology at Helmholtz Munich. "By combining our innovative CRISPR technology with Taconic’s expertise in animal model generation and breeding, we aim to accelerate the creation of precise models that uncover the genetic basis of diseases — supporting scientific discovery and paving the way for future medical breakthroughs.” 

By integrating novel CRISPR/Cas9 technologies with proven expertise in model generation, the collaboration supports the rapid development of scientific breakthroughs and improved translation of genetic research into therapeutic innovation.